AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38618204
Drug: Dexfadrostat phosphate
RxNorm normalized name: dextroamphetamine sulfate Oral Tablet [DextroStat]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfadrostat phosphate 4, 8, or 12 mg once daily for 8 weeks
Trial: 38618550
Drug: 36 g erythritol
RxNorm normalized name: Erythritol
DrugBank: Erythritol (DB04481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 g erythritol daily for 5 weeks
Trial: 38618550
Drug: 24 g xylitol
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 g xylitol daily for 5 weeks
Trial: 38619037
Drug: Teriflunomide (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriflunomide (14 mg adult-equivalent dose)
Trial: 38619178
Drug: sirolimus gel
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: sirolimus gel
Trial: 38620056
Drug: FlexHD prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FlexHD prophylactic biological mesh using sublay intraperitoneal technique
Trial: 38620056
Drug: FlexHD prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FlexHD prophylactic biological mesh
Trial: 38621178
Drug: Low-dose atropine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose atropine (various concentrations)
Trial: 38621393
Drug: Bictegravir (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bictegravir (30 mg), Emtricitabine (120 mg), Tenofovir Alafenamide (15 mg) once daily
Trial: 38621393
Drug: Bictegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir Alafenamide (25 mg) upon attaining a bodyweight of at least 25 kg
Trial: 38621405
Drug: Aerosol-inhaled live-attenuated
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol-inhaled live-attenuated Mycobacterium bovis BCG (BCG Danish strain and BCG Bulgaria strain)
Trial: 38621405
Drug: Intradermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermally administered BCG
Trial: 38621575
Drug: Edetate disodium
RxNorm normalized name: Edetate Disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edetate disodium (EDTA) chelation therapy
Trial: 38621624
Drug: SQ-LNS containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-LNS containing 15 mg zinc from ≥3 months before conception (preconception, arm 1)
Trial: 38621624
Drug: SQ-LNS containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-LNS containing 15 mg zinc from ∼12 weeks gestation through delivery (early pregnancy, arm 2)
Trial: 38621793
Drug: UPA 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UPA 15 mg QD
Trial: 38621793
Drug: UPA 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UPA 30 mg QD
Trial: 38621793
Drug: UPA 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UPA 15 mg QD and UPA 30 mg QD
Trial: 38622456
Drug: Pegsitacianine, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegsitacianine, administered intravenously at 1 mg/kg 24-72 hours before surgery
Trial: 38622543
Drug: Home Vision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home Vision Therapy Group (new near glasses with accommodative and convergence eye exercises)
Trial: 38622608
Drug: Weekly monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly monitoring by clinical teams
Trial: 38622671
Drug: Doppler-guided intraoperative
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doppler-guided intraoperative fluid replacement therapy with lactated Ringer's solution (n = 31)
Trial: 38622879
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin 1.8 mg/kg once every 3 weeks with R-CHP for six cycles
Trial: 38623494
Drug: Home-based titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based titration of levodopa duodenal infusions (LCIG)
Trial: 38625721
Drug: Previous tablet
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous tablet use
Trial: 38625800
Drug: Mavacamten (CAMZYOS),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten (CAMZYOS), dosage and duration not available
Trial: 38626363
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (target range 80-130 mg/dL)
Trial: 38626363
Drug: Standard sliding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sliding scale (80-179 mg/dL)
Trial: 38626363
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (intensive insulin vs standard sliding scale)
Trial: 38626958
Drug: 4CMenB (Bexsero)
RxNorm normalized name: Bexsero
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB (Bexsero) vaccine
Trial: 38626982
Drug: Paired serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paired serum samples for RSV antibodies
Trial: 38627035
Drug: Selinexor administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor administered at 60 mg weekly as maintenance therapy
Trial: 38627114
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation exercise (15 min daily for 4 weeks)
Trial: 38627137
Drug: Preoperative beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative beta-blockers
Trial: 38627238
Drug: Derazantinib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Derazantinib monotherapy (300 mg QD in Substudy 1, 200 mg BID in Substudy 5)
Trial: 38627238
Drug: Derazantinib 300
RxNorm normalized name: Derazantinib
DrugBank: Derazantinib (DB14889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Derazantinib 300 mg QD plus atezolizumab 1200 mg every 3 weeks (Substudy 2)
Trial: 38627238
Drug: Derazantinib 200
RxNorm normalized name: Derazantinib
DrugBank: Derazantinib (DB14889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Derazantinib 200 mg BID plus atezolizumab 1200 mg every 3 weeks (Substudy 3)
Trial: 38627238
Drug: Derazantinib 300
RxNorm normalized name: Derazantinib
DrugBank: Derazantinib (DB14889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Derazantinib 300 mg QD monotherapy (Substudy 4)
Trial: 38627238
Drug: Derazantinib 300
RxNorm normalized name: Derazantinib
DrugBank: Derazantinib (DB14889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Derazantinib 300 mg QD plus atezolizumab 1200 mg every 3 weeks (Substudy 4)
Trial: 38627266
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BLT) - 10,000 lx; daily 30-min sessions for 10 weeks
Trial: 38627366
Drug: TQ-B3525, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-B3525, 20 mg orally once daily in a 28-day cycle
Trial: 38627631
Drug: Placebo (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (calcium tablet)
Trial: 38627712
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (commercial electrochemical surface treatment)
Trial: 38627819
Drug: 3D-printed implant-retained
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D-printed implant-retained mandibular overdentures (IMO)
Trial: 38627837
Drug: 30 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 sessions of individual schema therapy
Trial: 38627837
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (mainly group-based, short-term cognitive behaviour or psychodynamic therapy)
Trial: 38628555
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (varenicline treatment)
Trial: 38629062
Drug: COVID-19 Ad5-nCoV
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 Ad5-nCoV adenovirus vaccine
Trial: 38629403
Drug: Narrative Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Therapy
Trial: 38629811
Drug: Ketamine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (initial bolus 0.23 mg/kg, continuous infusion 0.58 mg/kg/hr)
Trial: 38630186
Drug: Secondary furlow
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary furlow palatoplasty with buccal myomucosal flap (FPBF)
Trial: 38630457
Drug: Erenumab 140
RxNorm normalized name: Erenumab 140 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 140 mg subcutaneously every 4 weeks for 12 weeks
Trial: 38630471
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics monotherapy (moxifloxacin, 400 mg/d for 7 days)
Trial: 38630471
Drug: Combined IV
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined IV and oral antibiotics (IV ertapenem 1 g/d for 2 days plus oral levofloxacin 500 mg/d and metronidazole 500 mg 3 times/d for 5 days)
Trial: 38630524
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine alone
Trial: 38630524
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) and mindfulness meditation (MM) training
Trial: 38630524
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intravenous ketamine and CBT/MM
Trial: 38630525
Drug: Humidified high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humidified high-flow nasal oxygen, closed-mouth breathing, at 50 l min -1
Trial: 38630525
Drug: Standard nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nasal cannula, closed-mouth breathing, at 50 l min -1
Trial: 38630781
Drug: FAP-IL2v (fibroblast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAP-IL2v (fibroblast activation protein α-targeted IL2 variant) administered intravenously once weekly, starting dose 5 mg, with dose escalation up to 25 mg and various uptitration regimens.
Trial: 38630908
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin (2.5 mg/kg) plus pembrolizumab (200 mg)
Trial: 38630948
Drug: High-efficacy disease-modifying
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-efficacy disease-modifying treatments (H-DMT, n = 13)
Trial: 38630948
Drug: Lower-efficacy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-efficacy treatment
Trial: 38630948
Drug: High-efficacy disease-modifying
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-efficacy disease-modifying treatments (H-DMT)
Trial: 38631003
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg every 3 weeks for up to 17 cycles)
Trial: 38631679
Drug: Standard-of-care oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care oral hygiene regimen
Trial: 38631712
Drug: CNCT19 (anti-CD19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNCT19 (anti-CD19 CAR T-cell) after myeloablative high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT)
Trial: 38631764
Drug: Losmapimod (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod (15 mg twice a day)
Trial: 38631826
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg with metformin 1.5 g daily
Trial: 38631835
Drug: Stimulant and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant and Placebo
Trial: 38632117
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (antibiotics alone or in combination with percutaneous drainage)
Trial: 38632262
Drug: Subcutaneous teduglutide
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous teduglutide (n = 26)
Trial: 38632457
Drug: SPH3127 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH3127 50 mg
Trial: 38632457
Drug: SPH3127 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH3127 100 mg
Trial: 38632457
Drug: SPH3127 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH3127 200 mg
Trial: 38632501
Drug: EGCG nebulization
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG nebulization 10 ml three times daily for at least seven days, with dose escalation from 1760 umol/L to 8817 umol/L.
Trial: 38632501
Drug: EGCG nebulization
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG nebulization at 8817 umol/L.
Trial: 38632501
Drug: EGCG nebulization
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG nebulization treatment.
Trial: 38632647
Drug: Active theta-burst
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active theta-burst stimulation (TBS) to the left dorsolateral prefrontal cortex (DLPFC) and the vermis of the cerebellum, 1800 stimuli daily for 4 weeks.
Trial: 38632661
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: Treatment by ambulance crew and HEMS without prehospital ECPR capabilities
Trial: 38632826
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg subcutaneously every 4 weeks (Q4W)
Trial: 38632826
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg subcutaneously Q4W
Trial: 38633575
Drug: Frontline systemic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frontline systemic therapy at diagnosis or after observation
Trial: 38635115
Drug: Medication review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication review with follow-up (intervention group)
Trial: 38635245
Drug: Daily motion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily motion discrimination training in the intact field
Trial: 38635245
Drug: Daily motion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily motion discrimination training in the blind field
Trial: 38635272
Drug: Arthroscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic surgery plus nonoperative management (physical therapy plus medications)
Trial: 38635544
Drug: Mindfulness-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based physical exercise (MBPE) program, twice a week over 12 weeks
Trial: 38635932
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg orally once daily for 1 year
Trial: 38635932
Drug: Enzalutamide treatment
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide treatment
Trial: 38635934
Drug: Gemcitabine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine with ATR inhibitor berzosertib
Trial: 38636709
Drug: Genomic adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomic adjusted radiation dose (GARD)
Trial: 38636709
Drug: Concurrent chemo-radiotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemo-radiotherapy plus (neo) adjuvant chemotherapy
Trial: 38636725
Drug: DTG plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG plus two nucleoside reverse transcriptase inhibitors (NRTIs)
Trial: 38636818
Drug: Artificial Intelligence
RxNorm normalized name: Intelence
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artificial Intelligence (AI) assessment using the e-Boston Bowel Preparation Scale (e-BBPS)
Trial: 38637495
Drug: sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab (200 mg per 3 weeks)
Trial: 38637498
Drug: Virus-specific T
RxNorm normalized name: Allogeneic JC polyomavirus-specific T-cell therapy
DrugBank: CE-VST01-JC (DB17190)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virus-specific T cell (VST) therapy targeting cytomegalovirus, Epstein-Barr virus, or adenovirus
Trial: 38637498
Drug: Corticosteroids, graft-versus-host
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids, graft-versus-host disease, transplant-associated thrombotic microangiopathy, and eculizumab treatment
Trial: 38637755
Drug: Adjunctive registered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive registered nurse-based care (Quality Liver Nursing Care Model - QLiNCaM)
Trial: 38637772
Drug: External radiotherapy
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External radiotherapy (≥45 Gy, 2-2.5 Gy per fraction) followed by anti-PD-1 immunotherapy (camrelizumab 200 mg once every 3 weeks)
Trial: 38637829
Drug: Angiotensin-II treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-II treatment in ACEi/ARB-unexposed patients
Trial: 38637829
Drug: Angiotensin-II treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-II treatment in ACEi-exposed patients
Trial: 38637829
Drug: Angiotensin-II treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-II treatment in ARB-exposed patients
Trial: 38638180
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) and medical management
Trial: 38638399
Drug: Prophylactic metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic metformin plus endocrine therapy (ET)
Trial: 38638673
Drug: Zilucoplan 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilucoplan 0.3 mg/kg, self-administered subcutaneously, daily
Trial: 38638673
Drug: Zilucoplan 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilucoplan 0.3 mg/kg
Trial: 38638867
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (n = 10)
Trial: 38638867
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg (n = 12)
Trial: 38639433
Drug: Lurasidone (20-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (20-120 mg/d) with lithium
Trial: 38639433
Drug: Lurasidone (20-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (20-120 mg/d) with valproate
Trial: 38639433
Drug: Lurasidone (20-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (20-120 mg/d) with lithium or valproate
Trial: 38639940
Drug: Self-administered acupressure
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered acupressure (SAA) with brief knee health education (KHE); practiced twice daily for 12 weeks.
Trial: 38640068
Drug: OnabotulinumtoxinA low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA low dose (LD)
Trial: 38640068
Drug: OnabotulinumtoxinA high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA high dose (HD)
Trial: 38640200
Drug: Etavopivat 400
RxNorm normalized name: Etavopivat
DrugBank: Etavopivat (DB18176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etavopivat 400 mg once daily for 12 weeks (Open-label cohort)
Trial: 38640327
Drug: Turkish version
RxNorm normalized name: Turkish Licorice Root
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turkish version of the QoR-15 questionnaire (QoR-15T) administered preoperatively and 24 hours postoperatively
Trial: 38640500
Drug: Pudendal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudendal nerve block (PNB) with 20 mL of 0.5% bupivacaine